Patents by Inventor Stephen T. Isaacs

Stephen T. Isaacs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11998229
    Abstract: An ultrasonic surgical system is disclosed comprising a surgical instrument and a wrench assembly. The surgical instrument comprises a handle assembly and a body member pivotably coupled to the handle assembly. The handle assembly comprises a first finger grip, an ultrasonic blade, and a waveguide extending proximally from the ultrasonic blade. The body member comprises a second finger grip, a clamp arm movable relative to the ultrasonic blade to capture tissue therebetween, a first body surface defined on a first side of the body member, and a second body surface defined on a second side of the body member. The wrench assembly comprises a wrench and an adapter operably coupled to the wrench. The adapter comprises a first wrench surface configured to engage the first body surface and a second wrench surface configured to engage the second body surface.
    Type: Grant
    Filed: December 4, 2020
    Date of Patent: June 4, 2024
    Assignee: Cilag GmbH International
    Inventors: Stephen E. Eichmann, Karen K. Isaacs, Kenneth S. Kramer, Michael R. Lamping, Ashvani K. Madan, Matthew C. Miller, Aaron C. Voegele, Eitan T. Wiener, Joseph E. Young
  • Patent number: 6686480
    Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: February 3, 2004
    Assignee: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
  • Patent number: 6680025
    Abstract: A device containing a light source, a sample support and a temperature control compartment. The sample support is positioned to support multiple sample vessels for irradiation by the light source. The temperature control compartment maintains the temperature of the sample vessels within a desired range. The light source, sample support and temperature control compartment are all contained within an opaque housing.
    Type: Grant
    Filed: September 6, 2002
    Date of Patent: January 20, 2004
    Assignee: Cerus Corporation
    Inventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
  • Publication number: 20030185804
    Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
    Type: Application
    Filed: August 6, 2002
    Publication date: October 2, 2003
    Applicant: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
  • Publication number: 20030170141
    Abstract: A device comprising a light source, a sample support and a temperature control compartment. The sample support is positioned to support multiple sample vessels for irradiation by the light source. The temperature control compartment maintains the temperature of the sample vessels within a desired range. The light source, sample support and temperature control compartment are all contained within an opaque housing.
    Type: Application
    Filed: September 6, 2002
    Publication date: September 11, 2003
    Applicant: Cerus Corporation
    Inventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
  • Publication number: 20030105339
    Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.
    Type: Application
    Filed: June 3, 2002
    Publication date: June 5, 2003
    Applicant: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
  • Patent number: 6503699
    Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.
    Type: Grant
    Filed: August 16, 1999
    Date of Patent: January 7, 2003
    Assignee: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
  • Patent number: 6469052
    Abstract: The present invention includes compositions comprising new psoralens with either a 4 ′, or 5 ′primary amino substituent and a blood product that is suitable for in vivo use. The compositions are useful for the inactivation of pathogens in blood products such as platelets and plasma.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: October 22, 2002
    Assignee: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
  • Patent number: 6461567
    Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: October 8, 2002
    Assignee: Cerus Corporation
    Inventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
  • Patent number: 6420570
    Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.
    Type: Grant
    Filed: January 22, 2001
    Date of Patent: July 16, 2002
    Assignee: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
  • Publication number: 20020044885
    Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.
    Type: Application
    Filed: June 11, 2001
    Publication date: April 18, 2002
    Inventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
  • Publication number: 20020006393
    Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
    Type: Application
    Filed: January 22, 2001
    Publication date: January 17, 2002
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
  • Patent number: 6258319
    Abstract: A device comprising a light source, a sample holder and a temperature control chamber. The sample holder supports the vessels in a fixed relationship relative to the light source. The temperature control chamber surrounds the sample holder and vessels, so that a temperature control fluid may be passed around the sample vessels effectively maintaining the temperature of the sample vessels within a desired temperature range.
    Type: Grant
    Filed: September 4, 1998
    Date of Patent: July 10, 2001
    Assignee: Cerus Corporation
    Inventors: David Paul Hearst, George D. Cimino, John Eugene Hearst, Stephen T. Isaacs
  • Patent number: 6218100
    Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, use of 5′-primary aminoalkyl psoralens to inactivate pathogens in platelets is disclosed.
    Type: Grant
    Filed: July 24, 1997
    Date of Patent: April 17, 2001
    Assignee: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
  • Patent number: 6194139
    Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4′, 5′, and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
    Type: Grant
    Filed: September 28, 1999
    Date of Patent: February 27, 2001
    Assignee: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
  • Patent number: 6017691
    Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion.
    Type: Grant
    Filed: February 9, 1996
    Date of Patent: January 25, 2000
    Assignee: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
  • Patent number: 6004742
    Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic add of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular compounds with primary aminoalkyl substitutions on the 4' or 5' positions of psoralen are used to inactivate pathogens in blood products such as platelets.
    Type: Grant
    Filed: November 3, 1997
    Date of Patent: December 21, 1999
    Assignee: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
  • Patent number: 6004741
    Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention contemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 4' and 5' primary aminoalkyl psoralens are photoactivated in platelet preparations to inactivate pathogens.
    Type: Grant
    Filed: October 23, 1997
    Date of Patent: December 21, 1999
    Assignee: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio
  • Patent number: 5972593
    Abstract: Psoralen compound compositions are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which yet permit their binding to nucleic acid of pathogens. Reaction conditions that photoactivate these bound psoralens result in covalent crosslinking to nucleic acid, thereby inactivating the pathogen. Higher psoralen binding levels and lower mutagenicity results in safer, more efficient, and reliable inactivation of pathogens. In addition to the psoralen compositions, the invention contemplates inactivating methods using the new psoralens.
    Type: Grant
    Filed: March 30, 1998
    Date of Patent: October 26, 1999
    Assignee: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann
  • Patent number: 5871900
    Abstract: Psoralen compounds are synthesized which have substitutions on the 4, 4', 5', and 8 positions of the psoralen, which permit enhanced binding to nucleic acid of pathogens. Higher psoralen binding levels and lower mutagenicity are described, resulting in safer, more efficient, and reliable inactivation of pathogens in blood products. The invention compemplates inactivation methods using the new psoralens which do not compromise the function of blood products for transfusion. In particular, 5'-primary amino psoralens are photoactivated in order to inactivate pathogens in biological fluids.
    Type: Grant
    Filed: November 7, 1997
    Date of Patent: February 16, 1999
    Assignee: Cerus Corporation
    Inventors: Susan Wollowitz, Stephen T. Isaacs, Henry Rapoport, Hans Peter Spielmann, Aileen Nerio